Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.

Bosch-Vilaró A, Jacobs B, Pomella V, Abbasi Asbagh L, Kirkland R, Michel J, Singh S, Liu X, Kim P, Weitsman G, Barber PR, Vojnovic B, Ng T, Tejpar S.

Oncotarget. 2017 Jan 17;8(3):4277-4288. doi: 10.18632/oncotarget.13834.

2.

Nuclear p16INK4a expression predicts enhanced radiation response in head and neck cancers.

Dok R, Abbasi Asbagh L, Van Limbergen EJ, Sablina A, Nuyts S.

Oncotarget. 2016 Jun 21;7(25):38785-38795. doi: 10.18632/oncotarget.9609.

3.

Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.

Haesen D, Abbasi Asbagh L, Derua R, Hubert A, Schrauwen S, Hoorne Y, Amant F, Waelkens E, Sablina A, Janssens V.

Cancer Res. 2016 Oct 1;76(19):5719-5731. Epub 2016 Aug 2.

4.

Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism.

Cai Y, Crowther J, Pastor T, Abbasi Asbagh L, Baietti MF, De Troyer M, Vazquez I, Talebi A, Renzi F, Dehairs J, Swinnen JV, Sablina AA.

Cancer Cell. 2016 May 9;29(5):751-766. doi: 10.1016/j.ccell.2016.04.003.

5.

OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination.

Baietti MF, Simicek M, Abbasi Asbagh L, Radaelli E, Lievens S, Crowther J, Steklov M, Aushev VN, Martínez García D, Tavernier J, Sablina AA.

EMBO Mol Med. 2016 Mar 1;8(3):288-303. doi: 10.15252/emmm.201505972.

Supplemental Content

Loading ...
Support Center